<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJS</journal-id>
<journal-id journal-id-type="hwp">spijs</journal-id>
<journal-id journal-id-type="nlm-ta">Int J Surg Pathol</journal-id>
<journal-title>International Journal of Surgical Pathology</journal-title>
<issn pub-type="ppub">1066-8969</issn>
<issn pub-type="epub">1940-2465</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1066896911424898</article-id>
<article-id pub-id-type="publisher-id">10.1177_1066896911424898</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Primary Vaginal Ewing Sarcoma</article-title>
<subtitle>Case Report and Review of the Literature</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Bancalari</surname><given-names>Eugenia</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911424898">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>de Álava</surname><given-names>Enrique</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-1066896911424898">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tardío</surname><given-names>Juan C.</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1066896911424898">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1066896911424898"><label>1</label>Hospital Universitario de Fuenlabrada, Madrid, Spain</aff>
<aff id="aff2-1066896911424898"><label>2</label>University of Salamanca and Hospital Universitario de Salamanca, Salamanca, Spain</aff>
<author-notes>
<corresp id="corresp1-1066896911424898">Eugenia Bancalari, Servicio de Anatomía Patológica, Hospital Universitario de Fuenlabrada, Camino del Molino 2, 28942 Fuenlabrada, Madrid, Spain Email: <email>ebancalari.hflr@salud.madrid.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>20</volume>
<issue>3</issue>
<fpage>305</fpage>
<lpage>310</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Ewing sarcoma (ES) and primitive neuroectodermal tumor (PNET) are round-cell sarcomas with varying degrees of neuroectodermal differentiation; they are considered members of the same family of tumors based on their common genetic profile. ES/PNET are very infrequent in the female genital tract, the vagina being the rarest gynecological location, with 7 cases reported to date. The authors present a case of vaginal ES/PNET with typical morphological and immunohistochemical features. EWS gene rearrangement was demonstrated by fluorescent in situ hybridization analysis. Of the 7 previously reported cases, only 2 have molecular confirmation. The age at presentation for vaginal ES/PNET is slightly higher than that for these neoplasms in bone and soft tissues, with only 1 reported patient younger than 30 years. The outcome seems to be similar to that of other superficially sited ES/PNET and more favorable than for those observed in the more typical locations. However, the currently available data are limited, and therefore, a larger number of cases is necessary to draw any firm conclusions.</p>
</abstract>
<kwd-group>
<kwd>Ewing sarcoma</kwd>
<kwd>primitive neuroectodermal tumor</kwd>
<kwd>vagina</kwd>
<kwd>immunohistochemistry</kwd>
<kwd>fluorescent in situ hybridization</kwd>
<kwd><italic>EWS</italic> gene</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1066896911424898" sec-type="intro">
<title>Introduction</title>
<p>Ewing sarcoma (ES) and primitive neuroectodermal tumor (PNET) are round-cell sarcomas with varying degrees of neuroectodermal differentiation; they share a chromosomal aberration, consisting of a translocation leading to the fusion of the <italic>EWS</italic> gene on 22q12 with one of the members of the ETS family of transcription factors. The most frequent one is the t(11;22)(q24;q12), resulting in the fusion of the <italic>FLI1</italic> gene with the <italic>EWS</italic> gene, which presents in 85% of the ES/PNET cases. In the remaining cases, the variant t(21;22)(q22;q12) translocation is the most commonly found. The fusion genes resulting from these translocations encode novel chimeric transcription factors that are believed to contribute to the tumor biology by an aberrant regulation of gene expression, altering critical controls of cell proliferation and differentiation.<sup><xref ref-type="bibr" rid="bibr1-1066896911424898">1</xref></sup> Based on their common genetic features, ES and PNET are presently considered members of the same family of tumors, known as the Ewing family tumors. Those neoplasms that demonstrate neuroectodermal differentiation by light microscopy, immunohistochemistry, or ultrastructure have been called PNET, whereas the term <italic>Ewing sarcoma</italic> has been used for tumors that lack evidence of this type of differentiation.</p>
<p>ES/PNET usually present in patients younger than 20 years old as bone or deep soft-tissue masses. Nevertheless, examples have been reported in almost any anatomical site. They are histologically composed of uniform small round cells with round nuclei containing fine chromatin and scanty clear or eosinophilic cytoplasm. Tumors with larger cells and prominent nucleoli are also considered part of the spectrum of the Ewing family tumors. Virtually all cases show a characteristic membranous immunohistochemical expression of CD99.<sup><xref ref-type="bibr" rid="bibr2-1066896911424898">2</xref></sup></p>
<p>ES/PNET are uncommonly sited in the female genital tract, the vagina being the rarest gynecological location, with only 7 cases published to date.<sup><xref ref-type="bibr" rid="bibr3-1066896911424898">3</xref><xref ref-type="bibr" rid="bibr4-1066896911424898"/><xref ref-type="bibr" rid="bibr5-1066896911424898"/><xref ref-type="bibr" rid="bibr6-1066896911424898"/><xref ref-type="bibr" rid="bibr7-1066896911424898"/><xref ref-type="bibr" rid="bibr8-1066896911424898"/>-<xref ref-type="bibr" rid="bibr9-1066896911424898">9</xref></sup> Diagnosis is based on histological and immunohistochemical features and should be confirmed with molecular techniques because of its rarity. We herein present a case of primary vaginal ES/PNET with characteristic morphological, immunophenotypical, and molecular features.</p>
</sec>
<sec id="section2-1066896911424898" sec-type="cases">
<title>Case Report</title>
<p>A 39-year-old woman with no significant medical history presented with an episode of vaginal bleeding. Gynecological examination revealed a polypoid bleeding mass in the retrocervical posterior wall of the vagina. Pelvic ultrasound showed a normal uterus and adnexae, and a polypectomy was performed.</p>
<p>A fragmented polypectomy specimen was received by the department of pathology. It consisted of multiple gray-white, elastic tissue fragments, measuring 3.6 × 2.3 × 1.4 cm<sup>3</sup>. Microscopic examination revealed a highly cellular neoplastic proliferation located in the subepithelial connective tissue of the vaginal wall. It was composed of small- to medium-sized round cells, arranged in sheets without any specific architectural pattern (<xref ref-type="fig" rid="fig1-1066896911424898">Figure 1</xref>). The cells showed round or ovoid nuclei with finely stippled chromatin and small nucleoli and scanty, pale, occasionally clear cytoplasm with poorly defined margins (<xref ref-type="fig" rid="fig2-1066896911424898">Figure 2</xref>). Mitotic figures were numerous (mitotic index: 15/10 hpf). Some rosette-like structures were identified (<xref ref-type="fig" rid="fig3-1066896911424898">Figure 3</xref>). Foci of geographic necrosis and hemorrhagic areas could be easily found. Periodic acid–Schiff stain revealed cytoplasmic granules sensitive to diastase, which corresponded to glycogen (<xref ref-type="fig" rid="fig4-1066896911424898">Figure 4</xref>). The superficial epithelium was spared.</p>
<fig id="fig1-1066896911424898" position="float">
<label>Figure 1.</label>
<caption><p>A low-power view of the polypectomy specimen showing vaginal mucosa infiltrated by a blue, round small-cell tumor (hematoxylin and eosin, 40×)</p></caption>
<graphic xlink:href="10.1177_1066896911424898-fig1.tif"/>
</fig>
<fig id="fig2-1066896911424898" position="float">
<label>Figure 2.</label>
<caption><p>Sheets of uniform neoplastic cells arranged without any specific architectural pattern (hematoxylin and eosin, 100×)</p></caption>
<graphic xlink:href="10.1177_1066896911424898-fig2.tif"/>
</fig>
<fig id="fig3-1066896911424898" position="float">
<label>Figure 3.</label>
<caption><p>High-magnification view of the tumor exhibiting occasional rosettes (hematoxylin and eosin, 400×)</p></caption>
<graphic xlink:href="10.1177_1066896911424898-fig3.tif"/>
</fig>
<fig id="fig4-1066896911424898" position="float">
<label>Figure 4.</label>
<caption><p>Numerous cytoplasmic glycogen granules in the tumor cells (periodic acid–Schiff, 400×)</p></caption>
<graphic xlink:href="10.1177_1066896911424898-fig4.tif"/>
</fig>
<p>Immunohistochemical study was performed on paraffin-embedded tissue using a polymer-based detection system (EnVision; Dako, Glostrup, Denmark), which showed strong and diffuse membranous expression of CD99 (clone 12E7; dilution 1/25; source Dako; <xref ref-type="fig" rid="fig5-1066896911424898">Figure 5</xref>). In addition, positivity to vimentin (V9; 1/16000; Biogenex, San Ramon, CA) and lack of reactivity of the remaining markers used were found, including cytokeratin (AE1/AE3; 1/100; Dako), EMA (E29; 1/100; Dako), synaptophysin (SP11; 1/100; Master Diagnóstica, Granada, Spain), chromogranin A (DAK-A3; 1/200; Dako), CD45 (2B11+PD7/26; 1/100; Dako), CD34 (QBEnd-10; 1/50; Dako), CD10 (56C6; 1/25; Master Diagnóstica), muscle-specific actin (HHF35; 1/400; Dako), desmin (D33; 1/200; Dako), myoD1 (58A; 1/25; Dako), S-100 protein (polyclonal; 1/2000; Dako), and melan-A (A103; 1/50; Dako).</p>
<fig id="fig5-1066896911424898" position="float">
<label>Figure 5.</label>
<caption><p>Neoplastic cells showing diffuse and strong membranous CD99 positivity (CD99, 200×)</p></caption>
<graphic xlink:href="10.1177_1066896911424898-fig5.tif"/>
</fig>
<p>Fluorescent in situ hybridization (FISH) was performed with Breakapart EWS probes (Vysis; Abbott Laboratories. Abbott Park, IL). It revealed a <italic>EWS</italic> gene rearrangement in most tumor cells (<xref ref-type="fig" rid="fig6-1066896911424898">Figure 6</xref>). The pathological diagnosis was ES.</p>
<fig id="fig6-1066896911424898" position="float">
<label>Figure 6.</label>
<caption><p>Fluorescent in situ hybridization analysis exhibiting a signal pattern indicative of an <italic>EWS</italic> (Ewing sarcoma) gene rearrangement with separation of green and red signals, whereas normal signals remain fused (yellow)</p></caption>
<graphic xlink:href="10.1177_1066896911424898-fig6.tif"/>
</fig>
<p>After the diagnosis was rendered, repeated vaginoscopy showed a 4-mm cicatricial gray lesion where the polypectomy was taken, which disappeared in later gynecological examinations. Laboratory tests were normal. Physical examination, thoracoabdominal and pelvic computed tomography, pelvic nuclear magnetic resonance, bone scan, hysteroscopy, and bone marrow biopsy revealed no evidence of tumor.</p>
<p>The patient received 6 cycles of chemotherapy with ifosfamide-etoposide alternating with vincristine-doxorubicin-cyclophosphamide and, afterward, underwent total hysterectomy with partial excision of the vaginal posterior wall, including the margins of the previous tumorectomy. No residual tumor was observed. After surgery, 8 chemotherapy cycles were planned, but the patient had neutropenic fever with the first postsurgery cycle, which did not respond to growth factors, and the remaining chemotherapy cycles were suspended. Now, 20 months after diagnosis, she is well, with no evidence of disease.</p>
</sec>
<sec id="section3-1066896911424898" sec-type="discussion">
<title>Discussion</title>
<p>Extraskeletal ES/PNET are commonly located in bones and deep soft tissues of the extremities, although they may arise with a lesser frequency in other soft-tissue locations and, more rarely, in virtually any anatomical site. Location in the female genital tract is infrequent, with most of the cases reported in the ovary or uterus. Primary vaginal involvement is the rarest gynecological location, with only 7 cases reported to date.<sup><xref ref-type="bibr" rid="bibr3-1066896911424898">3</xref><xref ref-type="bibr" rid="bibr4-1066896911424898"/><xref ref-type="bibr" rid="bibr5-1066896911424898"/><xref ref-type="bibr" rid="bibr6-1066896911424898"/><xref ref-type="bibr" rid="bibr7-1066896911424898"/><xref ref-type="bibr" rid="bibr8-1066896911424898"/>-<xref ref-type="bibr" rid="bibr9-1066896911424898">9</xref></sup> In addition, there is 1 published report of a case in the rectovaginal septum.<sup><xref ref-type="bibr" rid="bibr10-1066896911424898">10</xref></sup></p>
<p>We herein present the eighth case of primary vaginal ES/PNET. Our diagnosis is supported by typical histological and immunohistochemical features and confirmed by the detection of EWS rearrangement using FISH analysis. Considering the 8 reported cases, including ours (<xref ref-type="table" rid="table1-1066896911424898">Table 1</xref>), the primary vaginal ES/PNET seems to occur in slightly older patients than the whole ES/PNET group. The age range is from 28 to 47 years (median, 32 years; mean, 34.8 years), with only 1 patient younger than 30 years, which is rare for ES/PNET in the usual locations. They present as painless, solid or solid and cystic masses, occasionally with bleeding or bloody discharge and most frequently sited in the posterior wall of the inferior third of the vagina. The size of the tumors ranges from 3 to 8 cm (median, 3.9 cm; mean, 4.6 cm). In all cases, the diagnoses were based on histological and immunohistochemical features, with only 3 of them, including ours, having molecular confirmation by RT-PCR (reverse transcriptase polymerase chain reaction) or FISH.<sup><xref ref-type="bibr" rid="bibr3-1066896911424898">3</xref>,<xref ref-type="bibr" rid="bibr7-1066896911424898">7</xref></sup></p>
<table-wrap id="table1-1066896911424898" position="float">
<label>Table 1.</label>
<caption><p>Reported Cases of Primary Vaginal ES/PNET: Clinical Data</p></caption>
<graphic alternate-form-of="table1-1066896911424898" xlink:href="10.1177_1066896911424898-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Author</th>
<th align="center">Age (years)</th>
<th align="center">Clinical Signs</th>
<th align="center">Size/Site</th>
<th align="center">Diagnosis</th>
<th align="center">Treatment</th>
<th align="center">Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vang et al<sup><xref ref-type="bibr" rid="bibr3-1066896911424898">3</xref></sup></td>
<td>35</td>
<td>Vaginal cystic mass</td>
<td>3 cm/NA</td>
<td>IHC + RT-PCR</td>
<td>S + CT + RT</td>
<td>NED 19 m</td>
</tr>
<tr>
<td>Farley et al<sup><xref ref-type="bibr" rid="bibr4-1066896911424898">4</xref></sup></td>
<td>35</td>
<td>Bloody discharge, vaginal cystic mass</td>
<td>4 cm/Posterior wall, distal third</td>
<td>IHC</td>
<td>S + CT + RT</td>
<td>NED 48 m</td>
</tr>
<tr>
<td>Gaona-Luviano et al<sup><xref ref-type="bibr" rid="bibr5-1066896911424898">5</xref></sup></td>
<td>34</td>
<td>Vaginal mass</td>
<td>3.8 cm/Posterior wall, distal third</td>
<td>IHC</td>
<td>S + CT + RT</td>
<td>NED 20 m</td>
</tr>
<tr>
<td>Liao et al<sup><xref ref-type="bibr" rid="bibr6-1066896911424898">6</xref></sup></td>
<td>30</td>
<td>Vaginal mass</td>
<td>5 cm/Posterior wall, distal third</td>
<td>IHC</td>
<td>S (HTDA) + RT + CT</td>
<td>NED 36 m</td>
</tr>
<tr>
<td>McCluggage et al<sup><xref ref-type="bibr" rid="bibr7-1066896911424898">7</xref></sup></td>
<td>30</td>
<td>Vaginal mass</td>
<td>8 cm/Anterior wall</td>
<td>IHC + RT-PCR</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Al-Tamimi et al<sup><xref ref-type="bibr" rid="bibr8-1066896911424898">8</xref></sup></td>
<td>47</td>
<td>Vaginal cystic mass</td>
<td>3 cm/Posterior wall, distal third</td>
<td>IHC</td>
<td>S + RT + CT</td>
<td>NED 3 m</td>
</tr>
<tr>
<td>Yip et al<sup><xref ref-type="bibr" rid="bibr9-1066896911424898">9</xref></sup></td>
<td>28</td>
<td>Cranial metastasis, vaginal nodule</td>
<td>4 cm/Right frontoparietal with epidural and scalp extension, 6 cm/introitus</td>
<td>IHC</td>
<td>S + RT + CT, partial resection + RT</td>
<td>NED 18 m (after cranial surgery)</td>
</tr>
<tr>
<td>Present case</td>
<td>39</td>
<td>Vaginal bleeding, polypoid vaginal mass</td>
<td>3.6 cm/Posterior wall, upper third</td>
<td>IHC + FISH</td>
<td>S (HTS) + CT</td>
<td>NED 20 m</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1066896911424898">
<p>Abbreviations: ES, Ewing sarcoma; PNE, primitive neuroectodermal tumor; Y, years; IHC, immunohistochemistry; RT-PCR, reverse transcriptase polymerase chain reaction; FISH, fluorescence in situ hybridization; S, surgery; RT, radiotherapy; CT, chemotherapy; HTS, simple hysterectomy; HTDA, hysterectomy with double anexectomy; NED, no evidence of disease; NA, data not available; m, months.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In the vagina, the differential diagnoses include undifferentiated carcinoma, small-cell neuroendocrine carcinoma, small-cell nonkeratinizing squamous carcinoma, malignant melanoma, lymphomas, leukemias, rhabdomyosarcomas, synovial sarcoma, and endometrial stromal sarcoma. The diagnosis is based on integration of clinical, morphological, immunohistochemical, and molecular findings because no isolated feature is completely specific for ES/PNET. CD99 is a highly sensitive immunohistochemical marker for this family of tumors, with strong membranous positivity observed in almost all cases.<sup><xref ref-type="bibr" rid="bibr11-1066896911424898">11</xref></sup> However, it can also be expressed in a variety of other neoplasms, including some that can enter the differential diagnoses—mainly lymphoblastic lymphomas<sup><xref ref-type="bibr" rid="bibr12-1066896911424898">12</xref></sup> and synovial sarcoma<sup><xref ref-type="bibr" rid="bibr13-1066896911424898">13</xref></sup> and in a minority of small-cell carcinomas.<sup><xref ref-type="bibr" rid="bibr14-1066896911424898">14</xref></sup> In a similar way, FLI1 immunostaining is found in most ES/PNET,<sup><xref ref-type="bibr" rid="bibr2-1066896911424898">2</xref></sup> but other tumors, such as lymphoblastic lymphomas,<sup><xref ref-type="bibr" rid="bibr15-1066896911424898">15</xref></sup> melanoma, Merkel cell carcinoma, and synovial sarcoma, can also express this antigen in a variable proportion of cases.<sup><xref ref-type="bibr" rid="bibr16-1066896911424898">16</xref></sup> Immunoreactivity for cytokeratins may be observed in about one fourth of ES/PNETs using AE1/AE3 or CAM 5.2 antibodies.<sup><xref ref-type="bibr" rid="bibr2-1066896911424898">2</xref>,<xref ref-type="bibr" rid="bibr17-1066896911424898">17</xref></sup> High-molecular-weight cytokeratins are expressed only in rare examples.<sup><xref ref-type="bibr" rid="bibr2-1066896911424898">2</xref></sup> Neuron-specific enolase, CD57, synaptophysin, and chromogranin A are positive in a variable number of ES/PNETs.<sup><xref ref-type="bibr" rid="bibr18-1066896911424898">18</xref></sup> Coexpression of cytokeratin and neuroendocrine markers can render the differential diagnosis difficult with small-cell carcinomas, which, as stated before, occasionally stain for CD99. The distinction is provided by the cytokeratin positivity pattern, which is focal and of a dot-like type in most ES/PNETs, and by the fact that vaginal carcinomas usually present in an older age group than ES/PNETs. Lack of stain for CD45 and other lymphoid markers, melanocytic antigens, myogenin, myoD1, and CD10 helps in the differentiation from leukemias and lymphomas, melanoma, rhabdomyosarcoma, and endometrial stromal sarcoma. Demonstration of the t(11;22)(q24;q12) or variant translocations by RT-PCR or rearrangement of the <italic>EWS</italic> gene by FISH is essential for confirming histologically or immunohistochemically nontypical cases or cases in rare locations, such as the vagina. These molecular findings, in the appropriate clinicopathological context, are virtually specific.<sup><xref ref-type="bibr" rid="bibr1-1066896911424898">1</xref></sup></p>
<p>The treatment the patient underwent is specified in 7 of the 8 vaginal ES/PNETs reported in the literature, including ours.<sup><xref ref-type="bibr" rid="bibr3-1066896911424898">3</xref><xref ref-type="bibr" rid="bibr4-1066896911424898"/><xref ref-type="bibr" rid="bibr5-1066896911424898"/>-<xref ref-type="bibr" rid="bibr6-1066896911424898">6</xref>,<xref ref-type="bibr" rid="bibr8-1066896911424898">8</xref>,<xref ref-type="bibr" rid="bibr9-1066896911424898">9</xref></sup> All of them underwent surgical resection of the mass, with subsequent total hysterectomy in 2, adjuvant chemoradiotherapy in 6, and adjuvant chemotherapy in 1 (<xref ref-type="table" rid="table1-1066896911424898">Table 1</xref>). Follow-up data are available in these 7 cases. One tumor metastasized to the frontoparietal scalp, skull, and dura 13 months after the partial resection of the vaginal mass, which was initially diagnosed as undifferentiated carcinoma and treated with radiotherapy.<sup><xref ref-type="bibr" rid="bibr9-1066896911424898">9</xref></sup> No other local recurrence or metastasis has been reported. All these 7 patients are alive with no evidence of disease 3 to 48 months after diagnosis (median, 20 months; mean, 23.4 months).<sup><xref ref-type="bibr" rid="bibr3-1066896911424898">3</xref><xref ref-type="bibr" rid="bibr4-1066896911424898"/><xref ref-type="bibr" rid="bibr5-1066896911424898"/>-<xref ref-type="bibr" rid="bibr6-1066896911424898">6</xref>,<xref ref-type="bibr" rid="bibr8-1066896911424898">8</xref>,<xref ref-type="bibr" rid="bibr9-1066896911424898">9</xref></sup> As previously reported for ES/PNETs located in the skin,<sup><xref ref-type="bibr" rid="bibr19-1066896911424898">19</xref></sup> the outcome for the primary vaginal cases seems to be more favorable than that for the whole ES/PNET group. This could be related to the small size, low stage at diagnosis, and easier complete surgical resection of the tumors in this location. Nevertheless, the number of cases is small and the follow-up admittedly short for drawing any sound conclusions.</p>
<p>In conclusion, the primary vaginal ES/PNET is a very rare neoplasm that usually presents as a painless mass in a slightly older age group compared with the whole ES/PNET group. Its diagnosis is based on histological and immunohistochemical features and should be confirmed by molecular techniques because of its rarity. Although the presently available data are limited—and, therefore, a larger number of cases is necessary for obtaining any firm conclusion—its outcome seems to be similar to that of other superficially sited ES/PNETs and more favorable than that observed for tumors in more typical locations.</p>
</sec>
</body>
<back>
<ack><p>The authors thank Teresa Hernández for her collaboration and for interpretation of molecular techniques.</p></ack>
<fn-group>
<fn fn-type="conflict">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1066896911424898">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Alava</surname><given-names>E</given-names></name>
<name><surname>Gerald</surname><given-names>WL</given-names></name>
</person-group>. <article-title>Molecular biology of the Ewing’s sarcoma/primitive neuroectodermal tumor family</article-title>. <source>J Clin Oncol</source>. <year>2000</year>;<volume>18</volume>:<fpage>204</fpage>-<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr2-1066896911424898">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Folpe</surname><given-names>AL</given-names></name>
<name><surname>Goldblum</surname><given-names>JR</given-names></name>
<name><surname>Rubin</surname><given-names>BP</given-names></name>
<etal/>
</person-group>. <article-title>Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases</article-title>. <source>Am J Surg Pathol</source>. <year>2005</year>;<volume>29</volume>:<fpage>1025</fpage>-<lpage>1033</lpage>.</citation>
</ref>
<ref id="bibr3-1066896911424898">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vang</surname><given-names>R</given-names></name>
<name><surname>Taubenberger</surname><given-names>JK</given-names></name>
<name><surname>Mannion</surname><given-names>CM</given-names></name>
<etal/>
</person-group>. <article-title>Primary vulvar and vaginal extraosseous Ewing’s sarcoma/peripheral neuroectodermal tumor: diagnostic confirmation with CD99 immunostaining and reverse transcriptase-polymerase chain reaction</article-title>. <source>Int J Gynecol Pathol</source>. <year>2000</year>;<volume>19</volume>:<fpage>103</fpage>-<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr4-1066896911424898">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Farley</surname><given-names>J</given-names></name>
<name><surname>O’Boyle</surname><given-names>JD</given-names></name>
<name><surname>Heaton</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Extraosseous Ewing sarcoma of the vagina</article-title>. <source>Obstet Gynecol</source>. <year>2000</year>;<volume>96</volume>:<fpage>832</fpage>-<lpage>834</lpage>.</citation>
</ref>
<ref id="bibr5-1066896911424898">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gaona-Luviano</surname><given-names>P</given-names></name>
<name><surname>Unda-Franco</surname><given-names>E</given-names></name>
<name><surname>González-Jara</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Case report: primitive neuroectodermal tumor of the vagina</article-title>. <source>Gynecol Oncol</source>. <year>2003</year>;<volume>91</volume>:<fpage>456</fpage>-<lpage>458</lpage>.</citation>
</ref>
<ref id="bibr6-1066896911424898">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liao</surname><given-names>X</given-names></name>
<name><surname>Xin</surname><given-names>X</given-names></name>
<name><surname>Lu</surname><given-names>X</given-names></name>
</person-group>. <article-title>Case report: primary Ewing’s sarcoma-primitive neuroectodermal tumor of the vagina</article-title>. <source>Gynecol Oncol</source>. <year>2004</year>;<volume>92</volume>:<fpage>684</fpage>-<lpage>688</lpage>.</citation>
</ref>
<ref id="bibr7-1066896911424898">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McCluggage</surname><given-names>WG</given-names></name>
<name><surname>Sumathi</surname><given-names>VP</given-names></name>
<name><surname>Nucci</surname><given-names>MR</given-names></name>
<etal/>
</person-group>. <article-title>Ewing family of tumors involving the vulva and the vagina: report of a series of four cases</article-title>. <source>J Clin Pathol</source>. <year>2007</year>;<volume>60</volume>:<fpage>674</fpage>-<lpage>680</lpage>.</citation>
</ref>
<ref id="bibr8-1066896911424898">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Al-Tamimi</surname><given-names>H</given-names></name>
<name><surname>Al-Hadi</surname><given-names>AA</given-names></name>
<name><surname>Al-Khater</surname><given-names>AH</given-names></name>
<etal/>
</person-group>. <article-title>Extraskeletal neuroectodermal tumor of the vagina: a single case report and review</article-title>. <source>Arch Gynecol Obstet</source>. <year>2009</year>;<volume>280</volume>:<fpage>465</fpage>-<lpage>468</lpage>.</citation>
</ref>
<ref id="bibr9-1066896911424898">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yip</surname><given-names>CM</given-names></name>
<name><surname>Hsu</surname><given-names>SS</given-names></name>
<name><surname>Chang</surname><given-names>NJ</given-names></name>
<etal/>
</person-group>. <article-title>Primary vaginal extraosseous Ewing sarcoma/primitive neuroectodermal tumor with cranial metastasis</article-title>. <source>J Chin Med Assoc</source>. <year>2009</year>;<volume>72</volume>:<fpage>332</fpage>-<lpage>335</lpage>.</citation>
</ref>
<ref id="bibr10-1066896911424898">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Petkovic</surname><given-names>M</given-names></name>
<name><surname>Zamolo</surname><given-names>G</given-names></name>
<name><surname>Muhvic</surname><given-names>D</given-names></name>
<name><surname>Coklo</surname><given-names>M</given-names></name>
<name><surname>Stifter</surname><given-names>S</given-names></name>
<name><surname>Antulov</surname><given-names>R</given-names></name>
</person-group>. <article-title>The first report of extraosseous Ewing’s sarcoma in the rectovaginal septum</article-title>. <source>Tumori</source>. <year>2002</year>;<volume>88</volume>:<fpage>345</fpage>-<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr11-1066896911424898">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perlman</surname><given-names>EJ</given-names></name>
<name><surname>Dickman</surname><given-names>PS</given-names></name>
<name><surname>Askin</surname><given-names>FB</given-names></name>
<name><surname>Grier</surname><given-names>HE</given-names></name>
<name><surname>Miser</surname><given-names>JS</given-names></name>
<name><surname>Link</surname><given-names>MP</given-names></name>
</person-group>. <article-title>Ewing’s sarcoma: routine diagnostic utilization of MIC2 analysis. A Pediatric Oncology Group/Children’s Cancer Group intergroup study</article-title>. <source>Hum Pathol</source>. <year>1994</year>;<volume>25</volume>:<fpage>304</fpage>-<lpage>307</lpage>.</citation>
</ref>
<ref id="bibr12-1066896911424898">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lucas</surname><given-names>DR</given-names></name>
<name><surname>Bentley</surname><given-names>G</given-names></name>
<name><surname>Dan</surname><given-names>ME</given-names></name>
<name><surname>Tabaczka</surname><given-names>P</given-names></name>
<name><surname>Poulik</surname><given-names>JM</given-names></name>
<name><surname>Mott</surname><given-names>MP</given-names></name>
</person-group>. <article-title>Ewing sarcoma vs lymphoblastic lymphoma: a comparative immunohistochemical study</article-title>. <source>Am J Clin Pathol</source>. <year>2001</year>;<volume>115</volume>:<fpage>11</fpage>-<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr13-1066896911424898">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pelmus</surname><given-names>M</given-names></name>
<name><surname>Guillou</surname><given-names>L</given-names></name>
<name><surname>Hostein</surname><given-names>I</given-names></name>
<name><surname>Sierankowski</surname><given-names>G</given-names></name>
<name><surname>Lussan</surname><given-names>C</given-names></name>
<name><surname>Coindre</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases</article-title>. <source>Am J Surg Pathol</source>. <year>2002</year>;<volume>26</volume>:<fpage>1434</fpage>-<lpage>1440</lpage>.</citation>
</ref>
<ref id="bibr14-1066896911424898">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lumadue</surname><given-names>JA</given-names></name>
<name><surname>Askin</surname><given-names>FB</given-names></name>
<name><surname>Perlman</surname><given-names>EJ</given-names></name>
</person-group>. <article-title>MIC2 analysis of small cell carcinoma</article-title>. <source>Am J Clin Pathol</source>. <year>1994</year>;<volume>102</volume>:<fpage>692</fpage>-<lpage>694</lpage>.</citation>
</ref>
<ref id="bibr15-1066896911424898">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Folpe</surname><given-names>AL</given-names></name>
<name><surname>Hill</surname><given-names>CE</given-names></name>
<name><surname>Parham</surname><given-names>DM</given-names></name>
<name><surname>O’Shea</surname><given-names>PA</given-names></name>
<name><surname>Weiss</surname><given-names>SW</given-names></name>
</person-group>. <article-title>Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing’s sarcoma/primitive neuroectodermal tumor</article-title>. <source>Am J Surg Pathol</source>. <year>2000</year>;<volume>24</volume>: <fpage>1657</fpage>-<lpage>1662</lpage>.</citation>
</ref>
<ref id="bibr16-1066896911424898">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rossi</surname><given-names>S</given-names></name>
<name><surname>Orvieto</surname><given-names>E</given-names></name>
<name><surname>Furlanetto</surname><given-names>A</given-names></name>
<name><surname>Laurino</surname><given-names>L</given-names></name>
<name><surname>Ninfo</surname><given-names>V</given-names></name>
<name><surname>Dei Tos</surname><given-names>AP</given-names></name>
</person-group>. <article-title>Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody</article-title>. <source>Mod Pathol</source>. <year>2004</year>;<volume>17</volume>: <fpage>547</fpage>-<lpage>552</lpage>.</citation>
</ref>
<ref id="bibr17-1066896911424898">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gu</surname><given-names>M</given-names></name>
<name><surname>Antonescu</surname><given-names>CR</given-names></name>
<name><surname>Guiter</surname><given-names>G</given-names></name>
<name><surname>Huvos</surname><given-names>AG</given-names></name>
<name><surname>Ladanyi</surname><given-names>M</given-names></name>
<name><surname>Zakowski</surname><given-names>MF</given-names></name>
</person-group>. <article-title>Cytokeratin immunoreactivity in Ewing’s sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies</article-title>. <source>Am J Surg Pathol</source>. <year>2000</year>;<volume>24</volume>:<fpage>410</fpage>-<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr18-1066896911424898">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Franchi</surname><given-names>A</given-names></name>
<name><surname>Pasquinelli</surname><given-names>G</given-names></name>
<name><surname>Cenacchi</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Immunohistochemical and ultrastructural investigation of differentiation in Ewing sarcoma/PNET of bone and soft tissues</article-title>. <source>Ultrastruct Pathol</source>. <year>2001</year>;<volume>25</volume>:<fpage>219</fpage>-<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr19-1066896911424898">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Terrier-Lacombe</surname><given-names>MJ</given-names></name>
<name><surname>Guillou</surname><given-names>L</given-names></name>
<name><surname>Chibon</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Superficial primitive Ewing’s sarcoma: a clinicopathologic and molecular cytogenetic analysis of 14 cases</article-title>. <source>Mod Pathol</source>. <year>2009</year>;<volume>22</volume>: <fpage>87</fpage>-<lpage>94</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>